Skip to main content
Betta Pharmaceuticals Co.,Ltd logo

Betta Pharmaceuticals Co.,Ltd — Investor Relations & Filings

Ticker · 300558 ISIN · CNE100002DD9 LEI · 8368009YF4Y6NC7HVB09 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 1,654 across all filing types
Latest filing 2021-09-27 Remuneration Information
Country CN China
Listing Shenzhen Stock Exchange 300558

About Betta Pharmaceuticals Co.,Ltd

https://www.bettapharma.com

Betta Pharmaceuticals Co.,Ltd. focuses on the research, development, and commercialization of innovative oncology medications. The organization specializes in targeted therapies, particularly for the treatment of lung cancer and other solid tumors. Its portfolio includes Icotinib, a small-molecule EGFR tyrosine kinase inhibitor, and Ensartinib, an ALK inhibitor designed for non-small cell lung cancer. The company operates a comprehensive R&D infrastructure dedicated to molecular biology, medicinal chemistry, and clinical development. By prioritizing precision medicine, the firm aims to deliver high-quality therapeutic solutions that address complex oncological challenges. Its pipeline encompasses a diverse range of candidates, including small molecules and biologics, aimed at improving patient outcomes through advanced scientific innovation.

Recent filings

Filing Released Lang Actions
2021年限制性股票激励计划首次授予激励对象名单（调整后）
Remuneration Information Classification · 95% confidence The document is titled as the "2021 年限制性股票激励计划首次授予激励对象名单（调整后）" which translates to "2021 Restricted Stock Incentive Plan First Grant Incentive Object List (Adjusted)". It contains detailed lists of directors, senior management, and core technical/business personnel who are recipients of restricted stock awards. The content focuses on the allocation of restricted stock incentives to company executives and employees, including quantities and proportions of shares granted. There is no indication of financial statements, audit opinions, earnings data, or regulatory certifications. The document is an announcement related to stock incentive plans and management share awards, which is best classified under Remuneration Information as it details compensation in the form of stock incentives for executives and key personnel.
2021-09-27 Chinese
关于调整2021年限制性股票激励计划首次授予激励对象名单及授予数量的公告
Regulatory Filings Classification · 95% confidence The document is an announcement from a company regarding adjustments to its 2021 restricted stock incentive plan, specifically about the first grant of restricted stock to incentive recipients. It details board and supervisory approvals, legal and financial advisor opinions, and changes in the number of shares and recipients. The document is relatively short (3242 characters) and focuses on the announcement of changes to a stock incentive plan rather than the full plan details or financial statements. It does not contain comprehensive financial data or detailed report content but rather a formal announcement of these adjustments and approvals. Therefore, it fits best as a Regulatory Filing (RNS) since it is a formal regulatory announcement about corporate governance and stock incentive adjustments without being a full report or financial statement.
2021-09-27 Chinese
关于向2021年限制性股票激励计划激励对象首次授予限制性股票的公告
Share Issue/Capital Change Classification · 95% confidence The document is a detailed announcement regarding the initial grant of restricted stock under the company's 2021 restricted stock incentive plan. It includes specifics about the grant date, number of shares, grant price, performance conditions, approval procedures, legal and financial opinions, and the impact on financials. The content focuses on the stock incentive plan and its implementation rather than financial results, earnings, or management changes. It is not a financial report, earnings release, or management discussion. It is also not a proxy statement or voting results announcement. The document is a formal announcement of a capital-related event (restricted stock grant) which is a form of equity compensation and capital change. Therefore, the most appropriate classification is Share Issue/Capital Change (SHA). The document length and detail confirm it is not a brief announcement or a report publication notice, but a substantive announcement of a capital change event.
2021-09-27 Chinese
独立董事关于第三届董事会第二十三次会议相关事项的独立意见
Board/Management Information Classification · 95% confidence The document is an independent director's opinion on matters discussed at the 23rd meeting of the third board of directors of Betta Pharmaceuticals Co., Ltd. It focuses on the adjustment and granting of restricted stock incentive plans in 2021. The content is related to governance and compliance with regulatory requirements regarding stock incentives, including legal and procedural reviews by independent directors. There are no financial statements or comprehensive financial data presented, nor is this a report of financial results or an announcement of voting results. The document is a formal governance-related opinion on board matters, specifically about stock incentive plans, which fits best under Board/Management Information (MANG). The document length is short (1834 characters), and it is not an announcement of a report publication or a certification letter, so it is not RPA or RNS.
2021-09-27 Chinese
关于2021年限制性股票激励计划内幕信息知情人及激励对象买卖公司股票情况的自查报告
Regulatory Filings Classification · 95% confidence The document is a self-inspection report regarding insider trading and stock transactions related to a 2021 restricted stock incentive plan by the company 贝达药业股份有限公司. It details the investigation scope, procedures, and findings about insider information holders and incentive recipients trading company stock. The document is a regulatory announcement about compliance and internal controls related to stock incentive plans and insider trading, not a financial report, earnings release, or management discussion. It does not contain financial statements or detailed financial data. It is a compliance and regulatory disclosure document related to insider trading and stock incentive plans, fitting best under Regulatory Filings (RNS). The document length is short (2036 characters), and it is a formal announcement rather than a full report or audit.
2021-09-22 Chinese
国浩律师（杭州）事务所关于贝达药业股份有限公司2021年第二次临时股东大会的法律意见书
Declaration of Voting Results & Voting Rights Announcements Classification · 95% confidence The document is a legal opinion letter issued by a law firm regarding the legality and validity of the procedures and voting results of a company's 2021 second extraordinary general meeting (临时股东大会). It details the convening, notification, attendance, voting procedures, and results of the shareholders' meeting. The document does not contain financial statements or financial performance data, nor is it a transcript or presentation. It is a legal opinion on the shareholder meeting process and results, which aligns with the category of Declaration of Voting Results & Voting Rights Announcements (DVA). The document length is sufficient and it is not merely an announcement of a report but a detailed legal opinion on the voting results and procedures. Therefore, the appropriate classification is DVA with high confidence.
2021-09-22 Chinese

Browse filings by year

11 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.